WB, IP, IHC-P, IF-F, IF-IC, FC-FP
H M R
Endogenous
62-82
Rabbit IgG
#P15884
6925
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:50 |
Immunohistochemistry (Paraffin) | 1:1500 - 1:6000 |
Immunofluorescence (Frozen) | 1:50 - 1:200 |
Immunofluorescence (Immunocytochemistry) | 1:1600 |
Flow Cytometry (Fixed/Permeabilized) | 1:3200 - 1:6400 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Bovine, Dog, Pig, Horse, Rabbit
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro653 of human TCF4/ITF2 protein.
Background
Transcription factor 4 (TCF4), also known as immunoglobulin transcription factor 2 (ITF2), is a member of the basic helix-loop-helix family and interacts with Ephrussi-box (E-box) binding sites (1,2). TCF4 is broadly expressed, and due to alternative splicing, transcripts can give rise to over a dozen different isoforms (3). It plays a key role in neuronal development and has been implicated in a variety of developmental disorders, including Pitt-Hopkins syndrome, schizophrenia, and autism (4-9). In addition to its functions in the brain, TCF4 is essential for the development of plasmacytoid dendritic cells (10-12). Finally, in the context of cancer, TCF4 expression may be associated with divergent patient outcomes; higher TCF4 expression is associated with increased survival in non-small cell lung cancer, yet the protein has also recently been reported to confer immunotherapy resistance in melanoma (13,14).
- Murre, C. et al. (1994) Biochim Biophys Acta 1218, 129-35.
- Furumura, M. et al. (2001) J Biol Chem 276, 28147-54.
- Sepp, M. et al. (2011) PLoS One 6, e22138.
- Flora, A. et al. (2007) Proc Natl Acad Sci USA 104, 15382-7.
- Brockschmidt, A. et al. (2007) Hum Mol Genet 16, 1488-94.
- Rannals, M.D. and Maher, B.J. (2017) Curr Genet Med Rep 5, 1-7.
- Stefansson, H. et al. (2009) Nature 460, 744-7.
- Mesman, S. et al. (2020) Mol Cell Neurosci 106, 103502.
- Papes, F. et al. (2022) Nat Commun 13, 2387.
- Nagasawa, M. et al. (2008) Eur J Immunol 38, 2389-400.
- Cisse, B. et al. (2008) Cell 135, 37-48.
- Dewald, H.K. et al. (2020) Viruses 12, 162.
- Pernía, O. et al. (2020) Cancers (Basel) 12, 786.
- Pozniak, J. et al. (2024) Cell 187, 166-183.e25.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin) IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.